See more : Schimatic Cash Transactions Network.com, Inc. (SCTN) Income Statement Analysis – Financial Results
Complete financial analysis of Sunnova Energy International Inc. (NOVA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sunnova Energy International Inc., a leading company in the Solar industry within the Energy sector.
- Buzzi Unicem S.p.A. (BZZUY) Income Statement Analysis – Financial Results
- Forgame Holdings Limited (0484.HK) Income Statement Analysis – Financial Results
- RavenQuest BioMed Inc. (RVVQF) Income Statement Analysis – Financial Results
- Crescent Capital BDC, Inc. (CCAP) Income Statement Analysis – Financial Results
- Cox & Kings Limited (COX&KINGS.NS) Income Statement Analysis – Financial Results
Sunnova Energy International Inc. (NOVA)
About Sunnova Energy International Inc.
Sunnova Energy International Inc. provides residential energy services in the United States. The company offers electricity, as well as offers operations and maintenance, monitoring, repairs and replacements, equipment upgrades, on-site power optimization, and diagnostics services. As of December 31, 2021, it operated a fleet of residential solar energy systems with a generation capacity of approximately 1,140 megawatts serving over 195,000 customers. Sunnova Energy International Inc. was incorporated in 2012 and is headquartered in Houston, Texas.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 720.65M | 557.69M | 241.75M | 160.82M | 131.56M | 104.38M | 76.86M |
Cost of Revenue | 427.50M | 327.08M | 98.31M | 65.18M | 47.41M | 36.72M | 27.34M |
Gross Profit | 293.16M | 230.61M | 143.44M | 95.64M | 84.14M | 67.67M | 49.52M |
Gross Profit Ratio | 40.68% | 41.35% | 59.34% | 59.47% | 63.96% | 64.82% | 64.43% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 430.42M | 302.00M | 204.24M | 115.15M | 97.99M | 67.43M | 54.86M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 430.42M | 302.00M | 204.24M | 115.15M | 97.99M | 67.43M | 54.86M |
Other Expenses | 106.17M | 10.11M | -5.90M | 16.27M | 8.43M | 13.97M | 5.01M |
Operating Expenses | 536.59M | 312.12M | 198.33M | 131.42M | 106.41M | 81.40M | 59.87M |
Cost & Expenses | 964.09M | 639.19M | 296.64M | 196.60M | 153.83M | 118.11M | 87.21M |
Interest Income | 115.87M | 59.80M | 34.23M | 23.74M | 12.48M | 6.45M | 3.20M |
Interest Expense | 371.94M | 107.78M | 116.25M | 154.58M | 112.12M | 61.13M | 83.02M |
Depreciation & Amortization | 181.82M | 136.61M | 106.95M | 66.10M | 49.36M | 39.29M | 29.48M |
EBITDA | 50.31M | 117.99M | 75.95M | -86.96M | 28.05M | 32.01M | 22.32M |
EBITDA Ratio | 6.18% | 21.16% | 35.48% | 34.69% | 29.40% | 24.62% | 29.05% |
Operating Income | -243.44M | -81.50M | -54.89M | -35.78M | -22.27M | -13.73M | -10.36M |
Operating Income Ratio | -33.78% | -14.61% | -22.71% | -22.25% | -16.93% | -13.15% | -13.47% |
Total Other Income/Expenses | -260.01M | -44.89M | -92.36M | -271.86M | -111.16M | -54.68M | -79.83M |
Income Before Tax | -503.45M | -126.39M | -147.25M | -307.64M | -133.43M | -68.41M | -90.18M |
Income Before Tax Ratio | -69.86% | -22.66% | -60.91% | -191.29% | -101.43% | -65.54% | -117.34% |
Income Tax Expense | -1.02M | 3.89M | 260.00K | 181.00K | 0.00 | 0.00 | 0.00 |
Net Income | -417.96M | -161.64M | -138.13M | -252.28M | -144.35M | -74.25M | -91.09M |
Net Income Ratio | -58.00% | -28.98% | -57.14% | -156.87% | -109.73% | -71.13% | -118.51% |
EPS | -3.53 | -1.41 | -1.25 | -2.87 | -4.14 | -1.63 | -1.46 |
EPS Diluted | -3.53 | -1.41 | -1.25 | -2.87 | -4.14 | -1.63 | -1.46 |
Weighted Avg Shares Out | 118.34M | 114.45M | 110.88M | 87.87M | 40.80M | 83.12M | 83.12M |
Weighted Avg Shares Out (Dil) | 118.34M | 114.45M | 110.88M | 87.87M | 40.80M | 83.12M | 83.12M |
3 Sorry Solar Stocks to Sell Now While You Still Can: Summer Edition
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
Why Solar Stocks First Solar, SunPower, and Sunnova Rocketed Higher Today
GoodWe C&I Solution Added to Sunnova's Approved Vendor List for US Market
Stock Market Crash Warning: Don't Get Caught Holding These 3 Solar Stocks
KBRA Assigns Preliminary Ratings to Sunnova Hestia II Issuer, LLC Solar Loan Backed Notes, Series 2024-GRID1
SunPower, SolarEdge, Sunnova stocks jumped: beware of this risk
Why Solar Energy Stocks Soared Today
Why Clean Energy Stocks Collapsed This Week
Sunnova Releases 2023 Sustainability Report, Delivering On its Efforts to Empower, Adapt, and Evolve
Source: https://incomestatements.info
Category: Stock Reports